Literature DB >> 19843513

Intrarenal artery superoxide is mainly NADPH oxidase-derived and modulates endothelium-dependent dilation in elderly patients.

Torsten Schlüter1, Uwe Zimmermann, Chris Protzel, Bärbel Miehe, Klaus-Jürgen Klebingat, Rainer Rettig, Olaf Grisk.   

Abstract

AIMS: The present study was performed to investigate the contribution of NADPH oxidases (Nox) to superoxide formation in human renal proximal resistance arteries and to test whether superoxide formation contributes to acute vasoconstrictor responses and endothelium-dependent vasodilation in these vessels. METHODS AND
RESULTS: Arcuate and proximal interlobular artery segments were from patients who underwent nephrectomy because of a renal tumour. Vessels were dissected from tumour-free parts of the kidneys. Additional intrarenal arteries were obtained from rats. Superoxide formation was measured by lucigenin-enhanced chemiluminescence, expression of Nox isoforms was analysed by RT-PCR, and functional studies were performed by small vessel wire myography. Sixty per cent of superoxide formation in human arcuate and proximal interlobular arteries was due to Nox activity. mRNA expression analyses revealed the presence of Nox2 and Nox4 but not Nox1. Phenylephrine and endothelin-1 induced powerful concentration-dependent vasoconstrictions that were unaffected by superoxide scavengers. Vasopressin elicited small and variable vasoconstrictions with signs of tachyphylaxis. Endothelium-dependent vasodilation was blunted by tiron and Nomega-nitro-L-arginine methyl ester but not by superoxide dismutase or catalase. Exogenous hydrogen peroxide elicited vasoconstriction.
CONCLUSION: Nox activity is the major source of superoxide formation in renal proximal resistance arteries from elderly patients. Acute vasoconstrictor responses to alpha1-adrenoreceptor activation and to endothelin-1 do not depend on superoxide formation, while endothelium-dependent vasodilation in intrarenal arteries is reactive oxygen species-dependent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843513     DOI: 10.1093/cvr/cvp346

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

Review 1.  Microvascular NADPH oxidase in health and disease.

Authors:  Yao Li; Patrick J Pagano
Journal:  Free Radic Biol Med       Date:  2017-03-06       Impact factor: 7.376

Review 2.  Oxidative stress, NADPH oxidases, and arteries.

Authors:  Qi-An Sun; Marschall S Runge; Nageswara R Madamanchi
Journal:  Hamostaseologie       Date:  2015-02-04       Impact factor: 1.778

Review 3.  NADPH oxidases, reactive oxygen species, and the kidney: friend and foe.

Authors:  Mona Sedeek; Rania Nasrallah; Rhian M Touyz; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 10.121

Review 4.  NOX1, 2, 4, 5: counting out oxidative stress.

Authors:  K Wingler; J J R Hermans; P Schiffers; Al Moens; M Paul; H H H W Schmidt
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  NADPH Oxidase Inhibition in Fibrotic Pathologies.

Authors:  Karen Bernard; Victor J Thannickal
Journal:  Antioxid Redox Signal       Date:  2020-03-04       Impact factor: 7.468

6.  Hydrogen peroxide derived from NADPH oxidase 4- and 2 contributes to the endothelium-dependent vasodilatation of intrarenal arteries.

Authors:  Mercedes Muñoz; María Pilar Martínez; María Elvira López-Oliva; Claudia Rodríguez; César Corbacho; Joaquín Carballido; Albino García-Sacristán; Medardo Hernández; Luis Rivera; Javier Sáenz-Medina; Dolores Prieto
Journal:  Redox Biol       Date:  2018-08-07       Impact factor: 11.799

7.  Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity.

Authors:  Mercedes Muñoz; Maria Elvira López-Oliva; Claudia Rodríguez; María Pilar Martínez; Javier Sáenz-Medina; Ana Sánchez; Belén Climent; Sara Benedito; Albino García-Sacristán; Luis Rivera; Medardo Hernández; Dolores Prieto
Journal:  Redox Biol       Date:  2019-09-20       Impact factor: 11.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.